Pro Medicus stock: CEO outlines FY2027 revenue step-up
Published on 11/17/2026 at 20:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth drivers strengthen the outlook
- Management said all six contracts due for renewal in FY2026 were extended for another five years at higher transaction rates.
- Trinity Health, University of Colorado and BayCare are expected to contribute a full year of revenue in the first half of FY2027.
- Cardiology sales and a new reporting module broaden Pro Medicus' growth opportunities.
At the Bell Potter Healthcare Conference on Monday, November 16, Pro Medicus management outlined a stronger FY2027 revenue profile after a record financial year. Investing.com reported that CEO Sam Hupert described FY2026 as a year of record revenue and earnings, with earnings up 26 percent year over year.
Renewals support recurring revenue
Pro Medicus said all six contracts due for renewal in FY2026 were renewed for another five years. The agreements were extended at higher transaction rates, while larger minimum volumes were negotiated for clients that had expanded through acquisitions.
Three major implementations - Trinity Health, University of Colorado and BayCare - were completed in the second half of FY2026. Management expects those deployments to provide a full-year contribution to transaction revenue in the first half of FY2027, creating a material step-up from the partial contribution in the previous financial year.
Cardiology and reporting expand reach
Cardiology is becoming a broader sales opportunity for the Visage 7 platform. Pro Medicus said it recently completed system sales at Tidal, Valley Health and Virtua, while MedStar and OSU added cardiology modules during renewal discussions.
The company also plans to launch a reporting module at the RSNA meeting in Chicago from November 29 to December 2. Management said the product will connect imaging data with clinical reports and target customers reviewing alternatives ahead of Microsoft's planned end of support for Nuance's on-premise reporting platform in August 2027.
Pro Medicus stock traded at 123.46 euros on Lang & Schwarz at 20:35 CET on Tuesday, November 17, 2026.
Pro Medicus Limited
- Company: Pro Medicus Limited
- ISIN: AU000000PME8
- Ticker: PME
- Home exchange: Australian Securities Exchange
- Lang & Schwarz quote: 123.46 euros at 20:35 CET on November 17, 2026
The S&P/ASX 200 market provides the broader Australian equity backdrop.
